Information on this Educational Activity
Disclosure of Conflicts of Interest
Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. PIM is committed to providing its learners with high quality CME activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.
The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:
Sanjiv S. Agarwala, MD
Professor of Medicine, Temple University
Chief, Medical Oncology & Hematology
St Luke's Cancer Center
Sanjiv S. Agarwala, MD, has no real or apparent conflicts of interest to report.
Alan J. Kivitz, MD, CPI
Altoona Arthritis and Osteoporosis Center
Altoona Center for Clinical Research
Alan J. Kivitz, MD, CPI, has disclosed that he has received consulting fees from AbbVie, Celgene, Genentech, Janssen, Merck, Novartis, Pfizer, Regeneron, Sanofi Genzyme, and UCB.
Rachael M. Andrie, PhD, has no real or apparent conflicts of interest to report.
Anna Poppa has no real or apparent conflicts of interest to report.
Jenny Schulz, PhD
Director, Scientific Services
Jenny Schulz, PhD, has no real or apparent conflicts of interest to report.
Zachary Schwartz, MSc, ELS, has no real or apparent conflicts of interest to report.
The planners and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:
The following PIM planners and managers, Trace Hutchison, PharmD, Samantha Mattiucci, PharmD, CHCP, Judi Smelker-Mitchek, RN, BSN and Jan Schultz, RN, MSN, CHCP, hereby state that they or their spouse/life partner do not have any financial relationships or relationships to products or devices with any commercial interest related to the content of this activity of any amount during the past 12 months.
Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.
The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
This program is intended for rheumatologists, gastroenterologists, oncologists, endocrinologists, and other healthcare professionals who are involved in the care of patients who may be eligible for treatment with biosimilars.
The goal of this activity is to improve clinicians’ understanding about biosimilars, focusing on the fundamental differences from small molecule generics and their reference biologics, as well as their safety, efficacy, and regulatory approval pathway.
Physician Continuing Medical Education
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Postgraduate Institute for Medicine and Clinical Care Options, LLC. The Postgraduate Institute for Medicine is accredited by the ACCME to provide continuing medical education for physicians.
The Postgraduate Institute for Medicine designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
This program has been made available online.
Instructions for Credit
Participation in this self-study activity should be completed in approximately 1.0 hours.
To successfully complete this activity and receive credit, participants must follow these steps during the period from
May 16, 2017, through May 15, 2018:
1. Register online at http://www.clinicaloptions.com.
2. Read the target audience, learning objectives, and faculty disclosures.
3. Study the educational activity online or printed out.
4. Submit answers to the posttest questions and evaluation questions online.
You must receive a test score of at least 65% and respond to all evaluation questions to receive a certificate.
After submitting the evaluation, you may access your online certificate by selecting the certificate link on the posttest confirmation page.
Records of all CME/CE activities completed can be found on the "CME/CE Manager" page. There are no costs/fees for this activity.